Espoo, Finland

Tuula Heinonen

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 3.7

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2002-2025

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Tuula Heinonen: Innovator in Cell Culture Technology

Introduction

Tuula Heinonen is a notable inventor based in Espoo, Finland. She has made significant contributions to the field of biotechnology, particularly in the development of innovative cell culture technologies. With a total of 2 patents, her work has implications for medical research and pharmaceutical applications.

Latest Patents

Heinonen's latest patents include a cell culture plate and a method for detecting substances. The cell culture plate features one or more wells that include at least one barrier, which divides the well into at least two compartments. This barrier is made from nanofibrillar cellulose hydrogel, enhancing the functionality of the plate. Additionally, she has developed a method for detecting substances, which involves a reference compound for analyzing levosimendan batches. This compound is a pyridazinyl derivative used to determine potentially genotoxic impurities in levosimendan samples, a medicament beneficial for treating heart failure.

Career Highlights

Throughout her career, Tuula Heinonen has worked with prominent companies such as Orion Corporation and UPM-Kymmene Corporation. Her experience in these organizations has allowed her to refine her skills and contribute to significant advancements in her field.

Collaborations

Heinonen has collaborated with esteemed colleagues, including Reijo Bäckström and Tuula Hauta-Aho. These partnerships have fostered innovation and have been instrumental in her research endeavors.

Conclusion

Tuula Heinonen's contributions to cell culture technology and her innovative patents highlight her role as a leading inventor in the biotechnology sector. Her work continues to influence medical research and pharmaceutical development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…